<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03697993</url>
  </required_header>
  <id_info>
    <org_study_id>15-0045</org_study_id>
    <secondary_id>HHSN272201300018I</secondary_id>
    <nct_id>NCT03697993</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Oral Fosfomycin Versus Oral Levofloxacin to Treat Complicated Urinary Syndromes (FOCUS)</brief_title>
  <official_title>Multi-center, Randomized, Open-label Trial to Evaluate the Efficacy of Oral Fosfomycin Versus Oral Levofloxacin Strategies in Complicated Urinary Tract Infections (FOCUS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 4, multi-center, open-label, randomized pragmatic superiority clinical trial&#xD;
      comparing two strategies for initial or step-down oral therapy for complicated urinary tract&#xD;
      infections (cUTI) after 0-48 hours of parenteral antibiotic therapy. The trial will evaluate&#xD;
      the success and safety of a strategy of initial or step-down fosfomycin, administered at a&#xD;
      dose of 3 g once daily, vs. a strategy of initial or step-down levofloxacin administered at a&#xD;
      dose of 750 mg once daily. Investigator-directed adjustment to another adequate oral therapy&#xD;
      is allowed 1) if the causative pathogen is not susceptible in vitro to quinolone initial or&#xD;
      step-down therapy in a subject randomized to the levofloxacin strategy, OR 2) if the subject&#xD;
      develops an intolerance or allergy to the initial step-down oral therapy and at the&#xD;
      investigator's discretion, OR 3) the subject has an underlying condition posing increasing&#xD;
      risk for adverse events from quinolone therapy. The duration of oral therapy (initial +&#xD;
      investigator-directed adjustment if indicated) in each strategy is 5-7 days of any per&#xD;
      protocol antibiotic to which the pathogen is susceptible. The dosing of oral therapy depends&#xD;
      on creatinine clearance (CrCl). The trial will enroll approximately 634 patients that are&#xD;
      either male or female aged 18 or older with cUTI from outpatient and inpatient settings. The&#xD;
      study will take place over 25 months in up to 15 US sites. The primary objective is to&#xD;
      compare Strategy 1 and Strategy 2 in terms of treatment success rates at Test of Cure (TOC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 4, multi-center, open-label, randomized pragmatic superiority clinical trial&#xD;
      comparing two strategies for initial or step-down oral therapy for complicated urinary tract&#xD;
      infections (cUTI) without bacteremia with a uropathogen after 0-48 hours of parenteral&#xD;
      antibiotic therapy. The trial will evaluate the success and safety of a strategy of initial&#xD;
      or step-down fosfomycin, administered at a dose of 3 g once daily, vs. a strategy of initial&#xD;
      or step-down levofloxacin administered at a dose of 750 mg once daily. Investigator-directed&#xD;
      adjustment to another adequate oral therapy is allowed 1) if the causative pathogen is not&#xD;
      susceptible in vitro to quinolone initial or step-down therapy in a subject randomized to the&#xD;
      levofloxacin strategy, OR 2) if the subject develops an intolerance or allergy to the initial&#xD;
      step-down oral therapy and at the investigator's discretion, OR 3) the subject has an&#xD;
      underlying condition posing increasing risk for adverse events from quinolone therapy. The&#xD;
      duration of oral therapy (initial + subsequent if indicated) in each strategy is 5-7 days of&#xD;
      any per protocol antibiotic to which the pathogen is susceptible. The dosing of oral therapy&#xD;
      depends on creatinine clearance (CrCl). The trial will enroll approximately 634 patients that&#xD;
      are either male or female aged 18 or older with cUTI from outpatient and inpatient settings.&#xD;
      The study will take place over 25 months in up to 15 US sites. The primary objective is to&#xD;
      compare Strategy 1 and Strategy 2 in terms of treatment success rates at Test of Cure (TOC).&#xD;
      The secondary objectives are: 1) to assess the safety of Fosfomycin; 2) to compare Strategy 1&#xD;
      and Strategy 2 in terms of solicited adverse events; 3) to compare Strategy 1 and Strategy 2&#xD;
      in terms of treatment success rates at End of Therapy (EOT).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    inadequate enrollment.&#xD;
  </why_stopped>
  <start_date type="Actual">November 7, 2018</start_date>
  <completion_date type="Actual">October 24, 2019</completion_date>
  <primary_completion_date type="Actual">October 24, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Treatment Success at Test of Cure (TOC)</measure>
    <time_frame>Day 21</time_frame>
    <description>Treatment success is defined as a combination of clinical cure and microbiological success.&#xD;
Clinical cure is defined as: 1) Resolution of UTI symptoms from presentation and 2) No new UTI symptoms and 3) Avoidance of parenteral antibiotic therapy, in or out of hospital, at any time after randomization OR oral antibiotic therapy different from per protocol.&#xD;
Microbiological success is defined as a reduction of the pathogen found at presentation to &lt;10^4 CFU/mL for non-catheter specimens or &lt;10^3 for catheter specimens on urine culture.&#xD;
A TOC visit was scheduled at 21 days (+7 days) after randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Solicited Adverse Events (AEs) Grade 2 and Above Among Those Who Received Fosfomycin</measure>
    <time_frame>Day 1 through Day 12</time_frame>
    <description>Solicited AEs are AEs that are common following administration of these types of antibiotics. The solicited AEs were collected after first dose of study product was given and until the end of therapy (EOT). If subject is on fosfomycin, solicited AEs were collected for 2 days after last dose of fosfomycin or until EOT, whichever occurs last. The solicited AEs includes insomnia, headache, dizziness, nausea, vomiting, constipation, diarrhea, back pain, rhinitis, pharyngitis, allergic reaction, and candidiasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Unsolicited Adverse Events (AEs) Grade 2 and Above Among Those Who Received Fosfomycin</measure>
    <time_frame>Day 1 through Day 12</time_frame>
    <description>The unsolicited AEs were collected in participants who received at least two doses of Fosfomycin from the time of second dose of Fosfomycin until the end of therapy (EOT) or 2 days after last dose of Fosfomycin, whichever occurs last.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Serious Adverse Events (SAEs) Among Those Who Received at Least Two Doses of Fosfomyci</measure>
    <time_frame>Day 1 through Day 21</time_frame>
    <description>SAEs included any untoward medical occurrence that resulted in death; was life threatening; was a persistent/significant disability/incapacity; required inpatient hospitalization or prolongation or a congenital anomaly/birth defect. Events are included if deemed by the investigator to be related to the study product. SAEs were only recorded in participants receiving at least two doses of fosfomyci.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Solicited Adverse Events (AEs)</measure>
    <time_frame>Day 1 through Day 21</time_frame>
    <description>Solicited AEs are AEs that are common following administration of these types of antibiotics. The solicited AEs were collected after first dose of study product was given and until the end of therapy (EOT). If subject is on fosfomycin, solicited AEs were collected for 2 days after last dose of fosfomycin or until EOT, whichever occurs last. The solicited AEs includes insomnia, headache, dizziness, nausea, vomiting, constipation, diarrhea, back pain, rhinitis, pharyngitis, allergic reaction, and candidiasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Solicited Adverse Events (AEs) by Severity</measure>
    <time_frame>Day 1 through Day 21</time_frame>
    <description>Solicited AEs are AEs that are common following administration of these types of antibiotics. The solicited AEs were collected after first dose of study product was given and until the end of therapy (EOT). If subject is on fosfomycin, solicited AEs were collected for 2 days after last dose of fosfomycin or until EOT, whichever occurs last. The solicited AEs includes insomnia, headache, dizziness, nausea, vomiting, constipation, diarrhea, back pain, rhinitis, pharyngitis, allergic reaction, and candidiasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Treatment Success at End of Therapy (EOT)</measure>
    <time_frame>Day 5 through Day 10</time_frame>
    <description>Treatment success is defined as a combination of clinical cure and microbiological success.&#xD;
Clinical cure is defined as: 1) Resolution of UTI symptoms from presentation and 2) No new UTI symptoms and 3) Avoidance of parenteral antibiotic therapy, in or out of hospital, at any time after randomization OR oral antibiotic therapy different from per protocol.&#xD;
Microbiological success is defined as a reduction of the pathogen found at presentation to &lt;10^4 CFU/mL for non-catheter specimens or &lt;10^3 for catheter specimens on urine culture.&#xD;
The EOT visit occured within 2 days of the completion of oral therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Urinary Tract Infection</condition>
  <arm_group>
    <arm_group_label>Strategy 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fosfomycin 3 g orally once daily for 5-7 days as initial or step-down oral therapy for complicated urinary tract infections (cUTI) without bacteremia with a uropathogen after 0-48 hours of parenteral antibiotic therapy, and if indicated a subsequent investigator-directed adjustment to another adequate oral therapy. N=317</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Strategy 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levofloxacin 750 mg orally once daily for 5-7 days as initial or step-down oral therapy for cUTI without bacteremia with a uropathogen after 0-48 hours of parenteral antibiotic therap, and if indicated a subsequent investigator-directed adjustment to another adequate oral therapy.y. N=317</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosfomycin tromethamine</intervention_name>
    <description>Administered orally as 3-gram single-dose sachet into 3-4 ounces (1 / 2 cup) of cool water; each dose must be taken immediately after dissolving in water. Hot water should not be used to dissolve fosfomycin. It may be taken either with or without food for normal kidney function. If Creatinine Clearance (CrCl) is less than 20 mL/min, fosfomycin should be taken as 3 grams every other day.</description>
    <arm_group_label>Strategy 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin</intervention_name>
    <description>750 mg is administered orally as one tablet once daily with or without food for normal kidney function. If Creatinine Clearance (CrCl) is 20-49 mL/min, 750 mg should be taken every other day. If on subsequent testing post-randomization, the Creatinine Clearance (CrCl) is less than 20 mL/min, followed by the dose is 500 mg every other day.</description>
    <arm_group_label>Strategy 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have documented clinical signs and/or symptoms of complicated urinary tract infection&#xD;
             (cUTI) at diagnosis*.&#xD;
&#xD;
             *Clinical signs and symptoms of cUTI include either:&#xD;
&#xD;
               1. Pyelonephritis, as indicated by at least 2 of the following:&#xD;
&#xD;
                    -  Documented fever (temperature greater than 38 degrees Celsius) accompanied&#xD;
                       by symptoms of rigors, chills, or &quot;warmth&quot;&#xD;
&#xD;
                    -  Flank pain&#xD;
&#xD;
                    -  Costovertebral angle tenderness on physical exam&#xD;
&#xD;
                    -  Nausea or vomiting&#xD;
&#xD;
                    -  Dysuria, urinary frequency, or urinary urgency OR&#xD;
&#xD;
               2. Complicated lower UTI, as indicated by at least 2 of the following new or&#xD;
                  worsening symptoms of cUTI:&#xD;
&#xD;
                    -  Dysuria, urinary frequency, or urinary urgency&#xD;
&#xD;
                    -  Documented fever (temperature greater than 38 degrees Celsius) accompanied&#xD;
                       by symptoms of rigors, chills, or &quot;warmth&quot;&#xD;
&#xD;
                    -  Documented hypothermia (temperature less than 35.5 degrees Celsius)&#xD;
&#xD;
                    -  Suprapubic pain or pelvic pain&#xD;
&#xD;
                    -  Suprapubic tenderness on physical exam&#xD;
&#xD;
                    -  New onset of foul smell to urine or increased cloudiness of urine per&#xD;
                       subject or their caregiver&#xD;
&#xD;
                    -  Nausea or vomiting&#xD;
&#xD;
             AND at least 1 of the following complicating factors:&#xD;
&#xD;
               -  Males with documented history of urinary retention&#xD;
&#xD;
               -  Indwelling urinary catheter that is planned to be removed or replaced during&#xD;
                  study therapy and before End of Therapy (EOT)&#xD;
&#xD;
               -  Current obstructive uropathy that is scheduled to be medically or surgically&#xD;
                  relieved during study therapy and before End of Therapy (EOT)&#xD;
&#xD;
               -  Any functional or anatomical abnormality of the urogenital tract (including&#xD;
                  anatomic malformations or neurogenic bladder) with voiding disturbance resulting&#xD;
                  in at least 100 mL of residual urine OR with the need for intermittent or ongoing&#xD;
                  self-catheterization.&#xD;
&#xD;
          2. Able to understand and provide written informed consent*. *A legally acceptable&#xD;
             representative may provide consent if the subject is unable to do so, provided this is&#xD;
             approved by local institution-specific guidelines.&#xD;
&#xD;
          3. Anticipated to be able to be stepped down or initially started on study oral&#xD;
             antibiotic therapy within 48 hours of enrollment*,**.&#xD;
&#xD;
             *The readiness of a subject for initial or step-down oral therapy is determined by the&#xD;
             primary medical team. In addition, for step down therapy the following conditions have&#xD;
             to be met: temperature at randomization must be less than 38 degrees Celsius without&#xD;
             any rigors/chills AND the subject must have an improvement in baseline symptoms of&#xD;
             cUTI and no new cUTI symptoms.&#xD;
&#xD;
             **Subject may be enrolled if he/she received a non-study oral antibiotic only if it is&#xD;
             followed by parenteral antibiotics for less than 48 hours prior to de-escalation with&#xD;
             study drugs.&#xD;
&#xD;
          4. Male or non-pregnant female.&#xD;
&#xD;
          5. Aged 18 years or older.&#xD;
&#xD;
          6. Women of childbearing potential* must agree to use an effective method of&#xD;
             contraception** for the duration of the trial.&#xD;
&#xD;
             *Female is considered of childbearing potential unless postmenopausal, or&#xD;
             surgically/non surgically sterilized and at least 3 months has passed since&#xD;
             sterilization procedure. A woman is considered postmenopausal if her last menstrual&#xD;
             period was greater than or equal to 12 months.&#xD;
&#xD;
             **Includes, but is not limited to, non-male sexual relationships, abstinence from&#xD;
             sexual intercourse with a male partner, monogamous relationship with vasectomized&#xD;
             partner who has been vasectomized for greater than or equal to 180 days before the&#xD;
             subject receiving the first dose of study drug, barrier methods such as condoms or&#xD;
             diaphragms, effective intrauterine devices, NuvaRing (R), and licensed hormonal&#xD;
             methods such as implants, injectables but not oral contraceptives.&#xD;
&#xD;
          7. If female of childbearing potential*, a negative urine or serum pregnancy test within&#xD;
             48 hours of randomization.&#xD;
&#xD;
             *Female is considered of childbearing potential unless postmenopausal, or&#xD;
             surgically/non surgically sterilized and at least 3 months has passed since&#xD;
             sterilization procedure. A woman is considered postmenopausal if her last menstrual&#xD;
             period was greater than or equal to 12 months.&#xD;
&#xD;
          8. Have pyuria (WBC count greater than or equal to 10/ÂµL in unspun urine or greater than&#xD;
             or equal to 10 per high power field in spun urine) or dipstick analysis positive&#xD;
             (excluding &quot;trace&quot;) for leukocyte esterase.&#xD;
&#xD;
          9. Have a pretreatment baseline urine culture specimen obtained within 48 hours before&#xD;
             the first dose of any antibiotic is administered (including pre-study antibiotics)*.&#xD;
&#xD;
             *Subjects may be enrolled in the trial and start study drug before the investigator&#xD;
             knows the results of the baseline urine culture.&#xD;
&#xD;
         10. Able to reliably take, tolerate, and absorb oral medications, at the investigator's&#xD;
             discretion.&#xD;
&#xD;
         11. Ability to understand study procedures and willing and able to comply with all&#xD;
             required procedures and visits for the duration of the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have a documented history of any moderate or severe hypersensitivity or allergic&#xD;
             reaction to all five oral therapy options.&#xD;
&#xD;
          2. Have a concomitant infection at the time of randomization, which requires non-study&#xD;
             systemic antibacterial therapy effective against complicated Urinary Tract Infection&#xD;
             (cUTI) in addition to study drug.&#xD;
&#xD;
          3. Have received more than 48 hours of a potentially therapeutic antibiotic for treatment&#xD;
             of the current cUTI within 72 hours before randomization*.&#xD;
&#xD;
             *Except if the following apply:&#xD;
&#xD;
               1. The subject has a known baseline urinary pathogen (urine culture positive) and&#xD;
                  has failed prior therapy clinically (persistence of inclusion criteria) AND&#xD;
&#xD;
               2. The pathogen is known to be non-susceptible to the previous therapeutic regimen&#xD;
                  used or the urine culture remains positive with a density of greater than or&#xD;
                  equal to 50,000 CFU/mL or greater than or equal to 10,000 for catheterized&#xD;
                  patients.&#xD;
&#xD;
          4. Women breastfeeding or donating breast milk.&#xD;
&#xD;
          5. Have intractable UTI infection at baseline that the investigator anticipates would&#xD;
             require more than 7 days of study drug therapy.&#xD;
&#xD;
          6. Have complete, permanent obstruction of the urinary tract*.&#xD;
&#xD;
             *Patients with complete permanent obstruction expected to be medically or surgically&#xD;
             treated prior to End of Treatment (EOT) are eligible.&#xD;
&#xD;
          7. Have confirmed fungal UTI at time of randomization (with greater than or equal to 10^3&#xD;
             fungal CFU/mL).&#xD;
&#xD;
          8. Have suspected or confirmed perinephric or intrarenal abscess.&#xD;
&#xD;
          9. Have suspected or confirmed prostatitis, epididymitis.&#xD;
&#xD;
         10. Have an ileal loop or known vesico-ureteral reflux.&#xD;
&#xD;
         11. Have a current urinary catheter that is not scheduled to be replaced before EOT*.&#xD;
&#xD;
             *Intermittent straight catheterization or replacement of new nephrostomy catheters is&#xD;
             acceptable.&#xD;
&#xD;
         12. Have planned inpatient urological intervention(s) for suspected infected kidney stone&#xD;
             or any other planned urological procedure with anticipated antibiotic prophylaxis&#xD;
             between randomization and End of Treatment (EOT).&#xD;
&#xD;
         13. Have bacteremia with a uropathogen causing cUTI.&#xD;
&#xD;
         14. Have an estimated or calculated Creatinine Clearance (CrCl) less than or equal to 20&#xD;
             mL/min or currently receiving hemo- or peritoneal dialysis at screening.&#xD;
&#xD;
         15. Have any condition or circumstance that, in the opinion of the investigator, would&#xD;
             compromise the safety of the subject or the quality of study data*.&#xD;
&#xD;
             *Including any rapidly progressing disease or immediately life-threatening (acute&#xD;
             hepatic failure, respiratory failure or septic shock).&#xD;
&#xD;
         16. Have participated in any interventional trial of an investigational product within 30&#xD;
             days before the proposed first day of study drug administration.&#xD;
&#xD;
         17. Plans to participate or currently enrolled in any interventional study of an&#xD;
             investigational agent for the duration of the trial.&#xD;
&#xD;
         18. Previous randomization in this trial.&#xD;
&#xD;
         19. Any recent (less than 4 weeks) history of trauma to the pelvis or urinary tract.&#xD;
&#xD;
         20. Prior fosfomycin use in the past 12 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California Los Angeles - Olive View Medical Center</name>
      <address>
        <city>Sylmar</city>
        <state>California</state>
        <zip>91342-1437</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor UCLA Medical Center - Medicine - Infectious Diseases</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502-2006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Vaccine Center - The Hope Clinic</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030-1705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Medicine - Department of Obstetrics and Gynecology - Division of Female Pelvic Medicine and Reconstructive Surgery</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa - Vaccine Research and Education Unit</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-2600</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Consultants - Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital - Infectious Diseases</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115-6110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System - Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202-2608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Truman Medical Center - Hospital Hill</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108-2640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U. of New Mexico Health Sciences Center - Dept. of Emergency Medicine</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>81731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center - Strong Memorial Hospital - Infectious Diseases</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital - Infectious Diseases and Immunology Center</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 11, 2018</verification_date>
  <study_first_submitted>October 4, 2018</study_first_submitted>
  <study_first_submitted_qc>October 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2018</study_first_posted>
  <results_first_submitted>October 15, 2020</results_first_submitted>
  <results_first_submitted_qc>November 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 19, 2020</results_first_posted>
  <last_update_submitted>November 19, 2020</last_update_submitted>
  <last_update_submitted_qc>November 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fosfomycin</keyword>
  <keyword>levofloxacin</keyword>
  <keyword>Open-label</keyword>
  <keyword>Phase IV</keyword>
  <keyword>UTI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Fosfomycin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 16, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT03697993/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 10, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT03697993/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were males and non-pregnant females aged &gt;=18 years and diagnosed with complicated urinary tract infections (cUTIs) without bacteremia with a uropathogen. Participants were enrolled between 14NOV2018 and 03OCT2019.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Strategy 1</title>
          <description>Fosfomycin 3 grams oral powder once daily for 5-7 days as initial or step-down oral therapy for cUTI without bacteremia with a uropathogen after 0-48 hours of parenteral antibiotic therapy, and if indicated a subsequent investigator-directed adjustment to another adequate oral therapy.&#xD;
Investigator-directed adjustment to another adequate oral therapy is allowed if the subject develops an intolerance or allergy to the initial step-down oral therapy and at the investigator's discretion, OR the subject has an underlying condition posing increased risk for adverse events from quinolone therapy. The duration of oral therapy (initial + subsequent if indicated) in each strategy is 5-7 days of any per protocol antibiotic to which the pathogen is susceptible. The dosing of oral therapy depends on creatinine clearance (CrCl).&#xD;
Another adequate oral therapy is defined as an oral therapy to which the pathogen shows in-vitro susceptibility AND to which the subject is tolerant based on history AND which is listed below:&#xD;
Levofloxacin 750 mg oral tablet once daily (Strategy 1 only)&#xD;
Amoxicillin-clavulanate 875/125 mg oral tablet twice daily&#xD;
Cefixime 400 mg oral tablet once daily&#xD;
Trimethoprim-sulfamethoxazole (TMP-SMX 160/800 mg) double-strength oral tablet twice daily</description>
        </group>
        <group group_id="P2">
          <title>Strategy 2</title>
          <description>Levofloxacin 750 mg oral tablet once daily for 5-7 days as initial or step-down oral therapy for cUTI without bacteremia with a uropathogen after 0-48 hours of parenteral antibiotic therapy, and if indicated a subsequent investigator-directed adjustment to another adequate oral therapy.&#xD;
Investigator-directed adjustment to another adequate oral therapy is allowed if the causative pathogen is not susceptible in vitro to quinolone initial or step-down therapy in a subject randomized to the levofloxacin strategy, OR if the subject develops an intolerance or allergy to the initial step-down oral therapy and at the investigator's discretion. The duration of oral therapy (initial + subsequent if indicated) in each strategy is 5-7 days of any per protocol antibiotic to which the pathogen is susceptible. The dosing of oral therapy depends on creatinine clearance (CrCl).&#xD;
Another adequate oral therapy is defined as an oral therapy to which the pathogen shows in-vitro susceptibility AND to which the subject is tolerant based on history AND which is listed below:&#xD;
Fosfomycin 3 grams oral powder once daily (Strategy 2 only)&#xD;
Amoxicillin-clavulanate 875/125 mg oral tablet twice daily&#xD;
Cefixime 400 mg oral tablet once daily&#xD;
Trimethoprim-sulfamethoxazole (TMP-SMX 160/800 mg) double-strength oral tablet twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Initiated Treatment</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Switched Treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6">Five (5) participants switched to Fosfomycin; 1 participant switched to Cefixime.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated With at Least Two Dose of Fosfomycin</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Became Ineligible after Enrollment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Enrolled but Treatment not Administered</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Initial Urine Culture Negative</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline analysis population includes all enrolled participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Strategy 1</title>
          <description>Fosfomycin 3 grams oral powder once daily for 5-7 days as initial or step-down oral therapy for cUTI without bacteremia with a uropathogen after 0-48 hours of parenteral antibiotic therapy, and if indicated a subsequent investigator-directed adjustment to another adequate oral therapy.&#xD;
Investigator-directed adjustment to another adequate oral therapy is allowed if the subject develops an intolerance or allergy to the initial step-down oral therapy and at the investigator's discretion, OR the subject has an underlying condition posing increased risk for adverse events from quinolone therapy. The duration of oral therapy (initial + subsequent if indicated) in each strategy is 5-7 days of any per protocol antibiotic to which the pathogen is susceptible. The dosing of oral therapy depends on creatinine clearance (CrCl).&#xD;
Another adequate oral therapy is defined as an oral therapy to which the pathogen shows in-vitro susceptibility AND to which the subject is tolerant based on history AND which is listed below:&#xD;
Levofloxacin 750 mg oral tablet once daily (Strategy 1 only)&#xD;
Amoxicillin-clavulanate 875/125 mg oral tablet twice daily&#xD;
Cefixime 400 mg oral tablet once daily&#xD;
Trimethoprim-sulfamethoxazole (TMP-SMX 160/800 mg) double-strength oral tablet twice daily</description>
        </group>
        <group group_id="B2">
          <title>Strategy 2</title>
          <description>Levofloxacin 750 mg oral tablet once daily for 5-7 days as initial or step-down oral therapy for cUTI without bacteremia with a uropathogen after 0-48 hours of parenteral antibiotic therapy, and if indicated a subsequent investigator-directed adjustment to another adequate oral therapy.&#xD;
Investigator-directed adjustment to another adequate oral therapy is allowed if the causative pathogen is not susceptible in vitro to quinolone initial or step-down therapy in a subject randomized to the levofloxacin strategy, OR if the subject develops an intolerance or allergy to the initial step-down oral therapy and at the investigator's discretion. The duration of oral therapy (initial + subsequent if indicated) in each strategy is 5-7 days of any per protocol antibiotic to which the pathogen is susceptible. The dosing of oral therapy depends on creatinine clearance (CrCl).&#xD;
Another adequate oral therapy is defined as an oral therapy to which the pathogen shows in-vitro susceptibility AND to which the subject is tolerant based on history AND which is listed below:&#xD;
Fosfomycin 3 grams oral powder once daily (Strategy 2 only)&#xD;
Amoxicillin-clavulanate 875/125 mg oral tablet twice daily&#xD;
Cefixime 400 mg oral tablet once daily&#xD;
Trimethoprim-sulfamethoxazole (TMP-SMX 160/800 mg) double-strength oral tablet twice daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.9" spread="19.4"/>
                    <measurement group_id="B2" value="46.3" spread="20.7"/>
                    <measurement group_id="B3" value="46.1" spread="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>cUTI</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Pyelonephritis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other cUTI</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.02" spread="7.52"/>
                    <measurement group_id="B2" value="29.29" spread="8.65"/>
                    <measurement group_id="B3" value="28.12" spread="8.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Treatment Success at Test of Cure (TOC)</title>
        <description>Treatment success is defined as a combination of clinical cure and microbiological success.&#xD;
Clinical cure is defined as: 1) Resolution of UTI symptoms from presentation and 2) No new UTI symptoms and 3) Avoidance of parenteral antibiotic therapy, in or out of hospital, at any time after randomization OR oral antibiotic therapy different from per protocol.&#xD;
Microbiological success is defined as a reduction of the pathogen found at presentation to &lt;10^4 CFU/mL for non-catheter specimens or &lt;10^3 for catheter specimens on urine culture.&#xD;
A TOC visit was scheduled at 21 days (+7 days) after randomization.</description>
        <time_frame>Day 21</time_frame>
        <population>The microbiologic Intention-to-Treat population includes all randomized participants who have a positive baseline bacterial culture of urine.</population>
        <group_list>
          <group group_id="O1">
            <title>Strategy 1</title>
            <description>Fosfomycin 3 grams oral powder once daily for 5-7 days as initial or step-down oral therapy for cUTI without bacteremia with a uropathogen after 0-48 hours of parenteral antibiotic therapy, and if indicated a subsequent investigator-directed adjustment to another adequate oral therapy.&#xD;
Investigator-directed adjustment to another adequate oral therapy is allowed if the subject develops an intolerance or allergy to the initial step-down oral therapy and at the investigator's discretion, OR the subject has an underlying condition posing increased risk for adverse events from quinolone therapy. The duration of oral therapy (initial + subsequent if indicated) in each strategy is 5-7 days of any per protocol antibiotic to which the pathogen is susceptible. The dosing of oral therapy depends on creatinine clearance (CrCl).&#xD;
Another adequate oral therapy is defined as an oral therapy to which the pathogen shows in-vitro susceptibility AND to which the subject is tolerant based on history AND which is listed below:&#xD;
Levofloxacin 750 mg oral tablet once daily (Strategy 1 only)&#xD;
Amoxicillin-clavulanate 875/125 mg oral tablet twice daily&#xD;
Cefixime 400 mg oral tablet once daily&#xD;
Trimethoprim-sulfamethoxazole (TMP-SMX 160/800 mg) double-strength oral tablet twice daily</description>
          </group>
          <group group_id="O2">
            <title>Strategy 2</title>
            <description>Levofloxacin 750 mg oral tablet once daily for 5-7 days as initial or step-down oral therapy for cUTI without bacteremia with a uropathogen after 0-48 hours of parenteral antibiotic therapy, and if indicated a subsequent investigator-directed adjustment to another adequate oral therapy.&#xD;
Investigator-directed adjustment to another adequate oral therapy is allowed if the causative pathogen is not susceptible in vitro to quinolone initial or step-down therapy in a subject randomized to the levofloxacin strategy, OR if the subject develops an intolerance or allergy to the initial step-down oral therapy and at the investigator's discretion. The duration of oral therapy (initial + subsequent if indicated) in each strategy is 5-7 days of any per protocol antibiotic to which the pathogen is susceptible. The dosing of oral therapy depends on creatinine clearance (CrCl).&#xD;
Another adequate oral therapy is defined as an oral therapy to which the pathogen shows in-vitro susceptibility AND to which the subject is tolerant based on history AND which is listed below:&#xD;
Fosfomycin 3 grams oral powder once daily (Strategy 2 only)&#xD;
Amoxicillin-clavulanate 875/125 mg oral tablet twice daily&#xD;
Cefixime 400 mg oral tablet once daily&#xD;
Trimethoprim-sulfamethoxazole (TMP-SMX 160/800 mg) double-strength oral tablet twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Treatment Success at Test of Cure (TOC)</title>
          <description>Treatment success is defined as a combination of clinical cure and microbiological success.&#xD;
Clinical cure is defined as: 1) Resolution of UTI symptoms from presentation and 2) No new UTI symptoms and 3) Avoidance of parenteral antibiotic therapy, in or out of hospital, at any time after randomization OR oral antibiotic therapy different from per protocol.&#xD;
Microbiological success is defined as a reduction of the pathogen found at presentation to &lt;10^4 CFU/mL for non-catheter specimens or &lt;10^3 for catheter specimens on urine culture.&#xD;
A TOC visit was scheduled at 21 days (+7 days) after randomization.</description>
          <population>The microbiologic Intention-to-Treat population includes all randomized participants who have a positive baseline bacterial culture of urine.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="36" upper_limit="73"/>
                    <measurement group_id="O2" value="73" lower_limit="54" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.264</p_value>
            <method>Multiple imputation using Wald method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.4</ci_lower_limit>
            <ci_upper_limit>8.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Solicited Adverse Events (AEs) Grade 2 and Above Among Those Who Received Fosfomycin</title>
        <description>Solicited AEs are AEs that are common following administration of these types of antibiotics. The solicited AEs were collected after first dose of study product was given and until the end of therapy (EOT). If subject is on fosfomycin, solicited AEs were collected for 2 days after last dose of fosfomycin or until EOT, whichever occurs last. The solicited AEs includes insomnia, headache, dizziness, nausea, vomiting, constipation, diarrhea, back pain, rhinitis, pharyngitis, allergic reaction, and candidiasis.</description>
        <time_frame>Day 1 through Day 12</time_frame>
        <population>The fosfomycin safety population includes all subjects treated with at least two doses of fosfomycin.</population>
        <group_list>
          <group group_id="O1">
            <title>Strategy 1</title>
            <description>Fosfomycin 3 grams oral powder once daily for 5-7 days as initial or step-down oral therapy for cUTI without bacteremia with a uropathogen after 0-48 hours of parenteral antibiotic therapy, and if indicated a subsequent investigator-directed adjustment to another adequate oral therapy.&#xD;
Investigator-directed adjustment to another adequate oral therapy is allowed if the subject develops an intolerance or allergy to the initial step-down oral therapy and at the investigator's discretion, OR the subject has an underlying condition posing increased risk for adverse events from quinolone therapy. The duration of oral therapy (initial + subsequent if indicated) in each strategy is 5-7 days of any per protocol antibiotic to which the pathogen is susceptible. The dosing of oral therapy depends on creatinine clearance (CrCl).&#xD;
Another adequate oral therapy is defined as an oral therapy to which the pathogen shows in-vitro susceptibility AND to which the subject is tolerant based on history AND which is listed below:&#xD;
Levofloxacin 750 mg oral tablet once daily (Strategy 1 only)&#xD;
Amoxicillin-clavulanate 875/125 mg oral tablet twice daily&#xD;
Cefixime 400 mg oral tablet once daily&#xD;
Trimethoprim-sulfamethoxazole (TMP-SMX 160/800 mg) double-strength oral tablet twice daily</description>
          </group>
          <group group_id="O2">
            <title>Strategy 2</title>
            <description>Levofloxacin 750 mg oral tablet once daily for 5-7 days as initial or step-down oral therapy for cUTI without bacteremia with a uropathogen after 0-48 hours of parenteral antibiotic therapy, and if indicated a subsequent investigator-directed adjustment to another adequate oral therapy.&#xD;
Investigator-directed adjustment to another adequate oral therapy is allowed if the causative pathogen is not susceptible in vitro to quinolone initial or step-down therapy in a subject randomized to the levofloxacin strategy, OR if the subject develops an intolerance or allergy to the initial step-down oral therapy and at the investigator's discretion. The duration of oral therapy (initial + subsequent if indicated) in each strategy is 5-7 days of any per protocol antibiotic to which the pathogen is susceptible. The dosing of oral therapy depends on creatinine clearance (CrCl).&#xD;
Another adequate oral therapy is defined as an oral therapy to which the pathogen shows in-vitro susceptibility AND to which the subject is tolerant based on history AND which is listed below:&#xD;
Fosfomycin 3 grams oral powder once daily (Strategy 2 only)&#xD;
Amoxicillin-clavulanate 875/125 mg oral tablet twice daily&#xD;
Cefixime 400 mg oral tablet once daily&#xD;
Trimethoprim-sulfamethoxazole (TMP-SMX 160/800 mg) double-strength oral tablet twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Adverse Events (AEs) Grade 2 and Above Among Those Who Received Fosfomycin</title>
          <description>Solicited AEs are AEs that are common following administration of these types of antibiotics. The solicited AEs were collected after first dose of study product was given and until the end of therapy (EOT). If subject is on fosfomycin, solicited AEs were collected for 2 days after last dose of fosfomycin or until EOT, whichever occurs last. The solicited AEs includes insomnia, headache, dizziness, nausea, vomiting, constipation, diarrhea, back pain, rhinitis, pharyngitis, allergic reaction, and candidiasis.</description>
          <population>The fosfomycin safety population includes all subjects treated with at least two doses of fosfomycin.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Unsolicited Adverse Events (AEs) Grade 2 and Above Among Those Who Received Fosfomycin</title>
        <description>The unsolicited AEs were collected in participants who received at least two doses of Fosfomycin from the time of second dose of Fosfomycin until the end of therapy (EOT) or 2 days after last dose of Fosfomycin, whichever occurs last.</description>
        <time_frame>Day 1 through Day 12</time_frame>
        <population>The fosfomycin safety population includes all subjects treated with at least two doses of fosfomycin.</population>
        <group_list>
          <group group_id="O1">
            <title>Strategy 1</title>
            <description>Fosfomycin 3 grams oral powder once daily for 5-7 days as initial or step-down oral therapy for cUTI without bacteremia with a uropathogen after 0-48 hours of parenteral antibiotic therapy, and if indicated a subsequent investigator-directed adjustment to another adequate oral therapy.&#xD;
Investigator-directed adjustment to another adequate oral therapy is allowed if the subject develops an intolerance or allergy to the initial step-down oral therapy and at the investigator's discretion, OR the subject has an underlying condition posing increased risk for adverse events from quinolone therapy. The duration of oral therapy (initial + subsequent if indicated) in each strategy is 5-7 days of any per protocol antibiotic to which the pathogen is susceptible. The dosing of oral therapy depends on creatinine clearance (CrCl).&#xD;
Another adequate oral therapy is defined as an oral therapy to which the pathogen shows in-vitro susceptibility AND to which the subject is tolerant based on history AND which is listed below:&#xD;
Levofloxacin 750 mg oral tablet once daily (Strategy 1 only)&#xD;
Amoxicillin-clavulanate 875/125 mg oral tablet twice daily&#xD;
Cefixime 400 mg oral tablet once daily&#xD;
Trimethoprim-sulfamethoxazole (TMP-SMX 160/800 mg) double-strength oral tablet twice daily</description>
          </group>
          <group group_id="O2">
            <title>Strategy 2</title>
            <description>Levofloxacin 750 mg oral tablet once daily for 5-7 days as initial or step-down oral therapy for cUTI without bacteremia with a uropathogen after 0-48 hours of parenteral antibiotic therapy, and if indicated a subsequent investigator-directed adjustment to another adequate oral therapy.&#xD;
Investigator-directed adjustment to another adequate oral therapy is allowed if the causative pathogen is not susceptible in vitro to quinolone initial or step-down therapy in a subject randomized to the levofloxacin strategy, OR if the subject develops an intolerance or allergy to the initial step-down oral therapy and at the investigator's discretion. The duration of oral therapy (initial + subsequent if indicated) in each strategy is 5-7 days of any per protocol antibiotic to which the pathogen is susceptible. The dosing of oral therapy depends on creatinine clearance (CrCl).&#xD;
Another adequate oral therapy is defined as an oral therapy to which the pathogen shows in-vitro susceptibility AND to which the subject is tolerant based on history AND which is listed below:&#xD;
Fosfomycin 3 grams oral powder once daily (Strategy 2 only)&#xD;
Amoxicillin-clavulanate 875/125 mg oral tablet twice daily&#xD;
Cefixime 400 mg oral tablet once daily&#xD;
Trimethoprim-sulfamethoxazole (TMP-SMX 160/800 mg) double-strength oral tablet twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Unsolicited Adverse Events (AEs) Grade 2 and Above Among Those Who Received Fosfomycin</title>
          <description>The unsolicited AEs were collected in participants who received at least two doses of Fosfomycin from the time of second dose of Fosfomycin until the end of therapy (EOT) or 2 days after last dose of Fosfomycin, whichever occurs last.</description>
          <population>The fosfomycin safety population includes all subjects treated with at least two doses of fosfomycin.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Serious Adverse Events (SAEs) Among Those Who Received at Least Two Doses of Fosfomyci</title>
        <description>SAEs included any untoward medical occurrence that resulted in death; was life threatening; was a persistent/significant disability/incapacity; required inpatient hospitalization or prolongation or a congenital anomaly/birth defect. Events are included if deemed by the investigator to be related to the study product. SAEs were only recorded in participants receiving at least two doses of fosfomyci.</description>
        <time_frame>Day 1 through Day 21</time_frame>
        <population>The Fosfomycin safety population includes all subjects treated with at least two doses of Fosfomycin.</population>
        <group_list>
          <group group_id="O1">
            <title>Strategy 1</title>
            <description>Fosfomycin 3 grams oral powder once daily for 5-7 days as initial or step-down oral therapy for cUTI without bacteremia with a uropathogen after 0-48 hours of parenteral antibiotic therapy, and if indicated a subsequent investigator-directed adjustment to another adequate oral therapy.&#xD;
Investigator-directed adjustment to another adequate oral therapy is allowed if the subject develops an intolerance or allergy to the initial step-down oral therapy and at the investigator's discretion, OR the subject has an underlying condition posing increased risk for adverse events from quinolone therapy. The duration of oral therapy (initial + subsequent if indicated) in each strategy is 5-7 days of any per protocol antibiotic to which the pathogen is susceptible. The dosing of oral therapy depends on creatinine clearance (CrCl).&#xD;
Another adequate oral therapy is defined as an oral therapy to which the pathogen shows in-vitro susceptibility AND to which the subject is tolerant based on history AND which is listed below:&#xD;
Levofloxacin 750 mg oral tablet once daily (Strategy 1 only)&#xD;
Amoxicillin-clavulanate 875/125 mg oral tablet twice daily&#xD;
Cefixime 400 mg oral tablet once daily&#xD;
Trimethoprim-sulfamethoxazole (TMP-SMX 160/800 mg) double-strength oral tablet twice daily</description>
          </group>
          <group group_id="O2">
            <title>Strategy 2</title>
            <description>Levofloxacin 750 mg oral tablet once daily for 5-7 days as initial or step-down oral therapy for cUTI without bacteremia with a uropathogen after 0-48 hours of parenteral antibiotic therapy, and if indicated a subsequent investigator-directed adjustment to another adequate oral therapy.&#xD;
Investigator-directed adjustment to another adequate oral therapy is allowed if the causative pathogen is not susceptible in vitro to quinolone initial or step-down therapy in a subject randomized to the levofloxacin strategy, OR if the subject develops an intolerance or allergy to the initial step-down oral therapy and at the investigator's discretion. The duration of oral therapy (initial + subsequent if indicated) in each strategy is 5-7 days of any per protocol antibiotic to which the pathogen is susceptible. The dosing of oral therapy depends on creatinine clearance (CrCl).&#xD;
Another adequate oral therapy is defined as an oral therapy to which the pathogen shows in-vitro susceptibility AND to which the subject is tolerant based on history AND which is listed below:&#xD;
Fosfomycin 3 grams oral powder once daily (Strategy 2 only)&#xD;
Amoxicillin-clavulanate 875/125 mg oral tablet twice daily&#xD;
Cefixime 400 mg oral tablet once daily&#xD;
Trimethoprim-sulfamethoxazole (TMP-SMX 160/800 mg) double-strength oral tablet twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Serious Adverse Events (SAEs) Among Those Who Received at Least Two Doses of Fosfomyci</title>
          <description>SAEs included any untoward medical occurrence that resulted in death; was life threatening; was a persistent/significant disability/incapacity; required inpatient hospitalization or prolongation or a congenital anomaly/birth defect. Events are included if deemed by the investigator to be related to the study product. SAEs were only recorded in participants receiving at least two doses of fosfomyci.</description>
          <population>The Fosfomycin safety population includes all subjects treated with at least two doses of Fosfomycin.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting Solicited Adverse Events (AEs)</title>
        <description>Solicited AEs are AEs that are common following administration of these types of antibiotics. The solicited AEs were collected after first dose of study product was given and until the end of therapy (EOT). If subject is on fosfomycin, solicited AEs were collected for 2 days after last dose of fosfomycin or until EOT, whichever occurs last. The solicited AEs includes insomnia, headache, dizziness, nausea, vomiting, constipation, diarrhea, back pain, rhinitis, pharyngitis, allergic reaction, and candidiasis.</description>
        <time_frame>Day 1 through Day 21</time_frame>
        <population>The safety population includes all enrolled participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Strategy 1</title>
            <description>Fosfomycin 3 grams oral powder once daily for 5-7 days as initial or step-down oral therapy for cUTI without bacteremia with a uropathogen after 0-48 hours of parenteral antibiotic therapy, and if indicated a subsequent investigator-directed adjustment to another adequate oral therapy.&#xD;
Investigator-directed adjustment to another adequate oral therapy is allowed if the subject develops an intolerance or allergy to the initial step-down oral therapy and at the investigator's discretion, OR the subject has an underlying condition posing increased risk for adverse events from quinolone therapy. The duration of oral therapy (initial + subsequent if indicated) in each strategy is 5-7 days of any per protocol antibiotic to which the pathogen is susceptible. The dosing of oral therapy depends on creatinine clearance (CrCl).&#xD;
Another adequate oral therapy is defined as an oral therapy to which the pathogen shows in-vitro susceptibility AND to which the subject is tolerant based on history AND which is listed below:&#xD;
Levofloxacin 750 mg oral tablet once daily (Strategy 1 only)&#xD;
Amoxicillin-clavulanate 875/125 mg oral tablet twice daily&#xD;
Cefixime 400 mg oral tablet once daily&#xD;
Trimethoprim-sulfamethoxazole (TMP-SMX 160/800 mg) double-strength oral tablet twice daily</description>
          </group>
          <group group_id="O2">
            <title>Strategy 2</title>
            <description>Levofloxacin 750 mg oral tablet once daily for 5-7 days as initial or step-down oral therapy for cUTI without bacteremia with a uropathogen after 0-48 hours of parenteral antibiotic therapy, and if indicated a subsequent investigator-directed adjustment to another adequate oral therapy.&#xD;
Investigator-directed adjustment to another adequate oral therapy is allowed if the causative pathogen is not susceptible in vitro to quinolone initial or step-down therapy in a subject randomized to the levofloxacin strategy, OR if the subject develops an intolerance or allergy to the initial step-down oral therapy and at the investigator's discretion. The duration of oral therapy (initial + subsequent if indicated) in each strategy is 5-7 days of any per protocol antibiotic to which the pathogen is susceptible. The dosing of oral therapy depends on creatinine clearance (CrCl).&#xD;
Another adequate oral therapy is defined as an oral therapy to which the pathogen shows in-vitro susceptibility AND to which the subject is tolerant based on history AND which is listed below:&#xD;
Fosfomycin 3 grams oral powder once daily (Strategy 2 only)&#xD;
Amoxicillin-clavulanate 875/125 mg oral tablet twice daily&#xD;
Cefixime 400 mg oral tablet once daily&#xD;
Trimethoprim-sulfamethoxazole (TMP-SMX 160/800 mg) double-strength oral tablet twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Solicited Adverse Events (AEs)</title>
          <description>Solicited AEs are AEs that are common following administration of these types of antibiotics. The solicited AEs were collected after first dose of study product was given and until the end of therapy (EOT). If subject is on fosfomycin, solicited AEs were collected for 2 days after last dose of fosfomycin or until EOT, whichever occurs last. The solicited AEs includes insomnia, headache, dizziness, nausea, vomiting, constipation, diarrhea, back pain, rhinitis, pharyngitis, allergic reaction, and candidiasis.</description>
          <population>The safety population includes all enrolled participants who received at least one dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="48.8" upper_limit="80.8"/>
                    <measurement group_id="O2" value="68" lower_limit="49.3" upper_limit="82.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.2</ci_lower_limit>
            <ci_upper_limit>24.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting Solicited Adverse Events (AEs) by Severity</title>
        <description>Solicited AEs are AEs that are common following administration of these types of antibiotics. The solicited AEs were collected after first dose of study product was given and until the end of therapy (EOT). If subject is on fosfomycin, solicited AEs were collected for 2 days after last dose of fosfomycin or until EOT, whichever occurs last. The solicited AEs includes insomnia, headache, dizziness, nausea, vomiting, constipation, diarrhea, back pain, rhinitis, pharyngitis, allergic reaction, and candidiasis.</description>
        <time_frame>Day 1 through Day 21</time_frame>
        <population>The safety population includes all enrolled participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Strategy 1</title>
            <description>Fosfomycin 3 grams oral powder once daily for 5-7 days as initial or step-down oral therapy for cUTI without bacteremia with a uropathogen after 0-48 hours of parenteral antibiotic therapy, and if indicated a subsequent investigator-directed adjustment to another adequate oral therapy.&#xD;
Investigator-directed adjustment to another adequate oral therapy is allowed if the subject develops an intolerance or allergy to the initial step-down oral therapy and at the investigator's discretion, OR the subject has an underlying condition posing increased risk for adverse events from quinolone therapy. The duration of oral therapy (initial + subsequent if indicated) in each strategy is 5-7 days of any per protocol antibiotic to which the pathogen is susceptible. The dosing of oral therapy depends on creatinine clearance (CrCl).&#xD;
Another adequate oral therapy is defined as an oral therapy to which the pathogen shows in-vitro susceptibility AND to which the subject is tolerant based on history AND which is listed below:&#xD;
Levofloxacin 750 mg oral tablet once daily (Strategy 1 only)&#xD;
Amoxicillin-clavulanate 875/125 mg oral tablet twice daily&#xD;
Cefixime 400 mg oral tablet once daily&#xD;
Trimethoprim-sulfamethoxazole (TMP-SMX 160/800 mg) double-strength oral tablet twice daily</description>
          </group>
          <group group_id="O2">
            <title>Strategy 2</title>
            <description>Levofloxacin 750 mg oral tablet once daily for 5-7 days as initial or step-down oral therapy for cUTI without bacteremia with a uropathogen after 0-48 hours of parenteral antibiotic therapy, and if indicated a subsequent investigator-directed adjustment to another adequate oral therapy.&#xD;
Investigator-directed adjustment to another adequate oral therapy is allowed if the causative pathogen is not susceptible in vitro to quinolone initial or step-down therapy in a subject randomized to the levofloxacin strategy, OR if the subject develops an intolerance or allergy to the initial step-down oral therapy and at the investigator's discretion. The duration of oral therapy (initial + subsequent if indicated) in each strategy is 5-7 days of any per protocol antibiotic to which the pathogen is susceptible. The dosing of oral therapy depends on creatinine clearance (CrCl).&#xD;
Another adequate oral therapy is defined as an oral therapy to which the pathogen shows in-vitro susceptibility AND to which the subject is tolerant based on history AND which is listed below:&#xD;
Fosfomycin 3 grams oral powder once daily (Strategy 2 only)&#xD;
Amoxicillin-clavulanate 875/125 mg oral tablet twice daily&#xD;
Cefixime 400 mg oral tablet once daily&#xD;
Trimethoprim-sulfamethoxazole (TMP-SMX 160/800 mg) double-strength oral tablet twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Solicited Adverse Events (AEs) by Severity</title>
          <description>Solicited AEs are AEs that are common following administration of these types of antibiotics. The solicited AEs were collected after first dose of study product was given and until the end of therapy (EOT). If subject is on fosfomycin, solicited AEs were collected for 2 days after last dose of fosfomycin or until EOT, whichever occurs last. The solicited AEs includes insomnia, headache, dizziness, nausea, vomiting, constipation, diarrhea, back pain, rhinitis, pharyngitis, allergic reaction, and candidiasis.</description>
          <population>The safety population includes all enrolled participants who received at least one dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53" lower_limit="36" upper_limit="70"/>
                    <measurement group_id="O2" value="50" lower_limit="33" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="5" upper_limit="30"/>
                    <measurement group_id="O2" value="18" lower_limit="8" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.894</p_value>
            <method>Proportional odds model using Wald test</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3</ci_lower_limit>
            <ci_upper_limit>2.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Treatment Success at End of Therapy (EOT)</title>
        <description>Treatment success is defined as a combination of clinical cure and microbiological success.&#xD;
Clinical cure is defined as: 1) Resolution of UTI symptoms from presentation and 2) No new UTI symptoms and 3) Avoidance of parenteral antibiotic therapy, in or out of hospital, at any time after randomization OR oral antibiotic therapy different from per protocol.&#xD;
Microbiological success is defined as a reduction of the pathogen found at presentation to &lt;10^4 CFU/mL for non-catheter specimens or &lt;10^3 for catheter specimens on urine culture.&#xD;
The EOT visit occured within 2 days of the completion of oral therapy.</description>
        <time_frame>Day 5 through Day 10</time_frame>
        <population>The microbiologic Intention-to-Treat population includes all randomized participants who have a positive baseline bacterial culture of urine.</population>
        <group_list>
          <group group_id="O1">
            <title>Strategy 1</title>
            <description>Fosfomycin 3 grams oral powder once daily for 5-7 days as initial or step-down oral therapy for cUTI without bacteremia with a uropathogen after 0-48 hours of parenteral antibiotic therapy, and if indicated a subsequent investigator-directed adjustment to another adequate oral therapy.&#xD;
Investigator-directed adjustment to another adequate oral therapy is allowed if the subject develops an intolerance or allergy to the initial step-down oral therapy and at the investigator's discretion, OR the subject has an underlying condition posing increased risk for adverse events from quinolone therapy. The duration of oral therapy (initial + subsequent if indicated) in each strategy is 5-7 days of any per protocol antibiotic to which the pathogen is susceptible. The dosing of oral therapy depends on creatinine clearance (CrCl).&#xD;
Another adequate oral therapy is defined as an oral therapy to which the pathogen shows in-vitro susceptibility AND to which the subject is tolerant based on history AND which is listed below:&#xD;
Levofloxacin 750 mg oral tablet once daily (Strategy 1 only)&#xD;
Amoxicillin-clavulanate 875/125 mg oral tablet twice daily&#xD;
Cefixime 400 mg oral tablet once daily&#xD;
Trimethoprim-sulfamethoxazole (TMP-SMX 160/800 mg) double-strength oral tablet twice daily</description>
          </group>
          <group group_id="O2">
            <title>Strategy 2</title>
            <description>Levofloxacin 750 mg oral tablet once daily for 5-7 days as initial or step-down oral therapy for cUTI without bacteremia with a uropathogen after 0-48 hours of parenteral antibiotic therapy, and if indicated a subsequent investigator-directed adjustment to another adequate oral therapy.&#xD;
Investigator-directed adjustment to another adequate oral therapy is allowed if the causative pathogen is not susceptible in vitro to quinolone initial or step-down therapy in a subject randomized to the levofloxacin strategy, OR if the subject develops an intolerance or allergy to the initial step-down oral therapy and at the investigator's discretion. The duration of oral therapy (initial + subsequent if indicated) in each strategy is 5-7 days of any per protocol antibiotic to which the pathogen is susceptible. The dosing of oral therapy depends on creatinine clearance (CrCl).&#xD;
Another adequate oral therapy is defined as an oral therapy to which the pathogen shows in-vitro susceptibility AND to which the subject is tolerant based on history AND which is listed below:&#xD;
Fosfomycin 3 grams oral powder once daily (Strategy 2 only)&#xD;
Amoxicillin-clavulanate 875/125 mg oral tablet twice daily&#xD;
Cefixime 400 mg oral tablet once daily&#xD;
Trimethoprim-sulfamethoxazole (TMP-SMX 160/800 mg) double-strength oral tablet twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Treatment Success at End of Therapy (EOT)</title>
          <description>Treatment success is defined as a combination of clinical cure and microbiological success.&#xD;
Clinical cure is defined as: 1) Resolution of UTI symptoms from presentation and 2) No new UTI symptoms and 3) Avoidance of parenteral antibiotic therapy, in or out of hospital, at any time after randomization OR oral antibiotic therapy different from per protocol.&#xD;
Microbiological success is defined as a reduction of the pathogen found at presentation to &lt;10^4 CFU/mL for non-catheter specimens or &lt;10^3 for catheter specimens on urine culture.&#xD;
The EOT visit occured within 2 days of the completion of oral therapy.</description>
          <population>The microbiologic Intention-to-Treat population includes all randomized participants who have a positive baseline bacterial culture of urine.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="47" upper_limit="82"/>
                    <measurement group_id="O2" value="67" lower_limit="49" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.973</p_value>
            <method>Multiple imputation using Wald method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.3</ci_lower_limit>
            <ci_upper_limit>25.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The solicited events were collected after first dose of study product was given and until the end of therapy (EOT). If subject was on fosfomycin, solicited AEs were collected for 2 days after last dose of fosfomycin or until EOT, whichever occurred last. The unsolicited AEs were collected in participants who received at least two doses of Fosfomycin from the time of second dose of fosfomycin until the end of therapy (EOT) or 2 days after last dose of fosfomycin, whichever occurred last.</time_frame>
      <desc>Serious Adverse Events (SAEs) were only recorded in participants receiving at least two doses of fosfomycin and were not collected for other interventions. Therefore the at risk population for SAE is a subset of the safety population who received any study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fosfomycin</title>
          <description>Fosfomycin was administered orally as a single 3 gram dose sachet once daily for normal kidney function or every other day for CrCl less than or equal to 20 mL/min.</description>
        </group>
        <group group_id="E2">
          <title>Levofloxacin</title>
          <description>Levofloxacin was administered orally as 750 mg tablet once daily for normal kidney function, 750 mg tablet every other day for CrCl 20-49 mL/min; 500 mg tablet every other day for CrCl &lt;20 mL/min.</description>
        </group>
        <group group_id="E3">
          <title>Cefixime</title>
          <description>Cefixime was administered orally as 400mg tablet or capsule once daily for normal kidney function; 260 mg of oral suspension once daily for subjects with CrCl between 21-59 mL/min; 200 mg chewable table once daily for subjects with CrCl less than or equal to 20 mL/min.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="57" subjects_affected="19" subjects_at_risk="35"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E2" events="15" subjects_affected="7" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="16" subjects_affected="8" subjects_at_risk="35"/>
                <counts group_id="E2" events="14" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="10" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E2" events="16" subjects_affected="7" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nadine Rouphael, MD, MSc</name_or_title>
      <organization>Vaccine Treatment Evaluation Unit (VTEU)</organization>
      <phone>(404) 822-1411</phone>
      <email>nroupha@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

